Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 3
2012 6
2013 5
2014 7
2015 9
2016 12
2017 17
2018 11
2019 15
2020 20
2021 22
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33246974

102 results
Results by year
Filters applied: . Clear all
Page 1
Interim PET in Diffuse Large B-Cell Lymphoma.
Kurch L, Hüttmann A, Georgi TW, Rekowski J, Sabri O, Schmitz C, Kluge R, Dührsen U, Hasenclever D. Kurch L, et al. J Nucl Med. 2021 Aug 1;62(8):1068-1074. doi: 10.2967/jnumed.120.255034. Epub 2020 Nov 27. J Nucl Med. 2021. PMID: 33246974
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method.
Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, Franzius C, Weckesser M, Bengel FM, Freesmeyer M, Hertel A, Krohn T, Holzinger J, Brink I, Haberkorn U, Nyuyki F, van Assema DME, Geworski L, Hasenclever D, Jöckel KH, Dührsen U. Rekowski J, et al. J Nucl Med. 2021 Jan;62(1):37-42. doi: 10.2967/jnumed.120.244145. Epub 2020 May 8. J Nucl Med. 2021. PMID: 32385164 Clinical Trial.
qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, Landman-Parker J, Moryl-Bujakowska A, Cepelová M, Karlén J, Álvarez Fernández-Teijeiro A, Attarbaschi A, Fosså A, Pears J, Hraskova A, Bergsträsser E, Beishuizen A, Uyttebroeck A, Schomerus E, Sabri O, Körholz D, Kluge R. Hasenclever D, et al. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1301-8. doi: 10.1007/s00259-014-2715-9. Epub 2014 Mar 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24604592
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C. Kurch L, et al. Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14. Pediatr Blood Cancer. 2019. PMID: 30426671
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzius C, Ganser A, Bengel FM, Kroschinsky F, Kotzerke J, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Mesters R, Weckesser M, Mahlmann S, Haberkorn U, Martens U, Prange-Krex G, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann A. Schmitz C, et al. Hematol Oncol. 2020 Aug;38(3):244-256. doi: 10.1002/hon.2697. Epub 2020 Feb 18. Hematol Oncol. 2020. PMID: 32067259
102 results